What Is Pacira BioSciences, Inc. (PCRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pacira BioSciences, Inc. presents a highly debated valuation profile at its current price of $25.54. The composite intrinsic value is estimated at $32.97 (+29.1% average upside), masking a wide model spread between the 6 bullish models and 6 bearish models. Model dispersion is worth noting: RCMH-DCF targets $80.53 (+215.3%), versus Regime Cross at $2.85 (-88.8%). This +304.1% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About PCRX?
13 of 13 models are currently active for PCRX. Of these, 7 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates PCRX's intrinsic value at $75.04, implying +193.8% upside from the current price. See which stocks rank higher →
How Does PCRX Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, PCRX ranks #42 by Quality of Company score. CirclFi's QOC score of 7.6/10 evaluates 32 fundamental signals. A score of 7.6 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Pacira BioSciences, Inc. competes in an environment where FDA approval probability often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is PCRX a Value Trap?
CirclFi's Value Trap algorithm assigns PCRX a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Pacira BioSciences, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Pacira BioSciences, Inc. is rated at 7.6/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.
The gap between the most bullish and bearish model spans +304.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PCRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PCRX's 13 active models, average confidence is 43%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad